Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model

Journal of Immunology

Volumn 187, Issue 2, 2011, Pages 1015-1022

  Patel, Dipesh A ^a   Puig Canto, Alberto ^a   Challa, Dilip Kumar ^a   Montoyo, Héctor Perez ^a,c   Ober, Raimund J ^a,b   Ward, E Sally ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b The University of Texas at Dallas   (United States)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIBODY; FC RECEPTOR; FC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BLOCKING; ANTIBODY AFFINITY; ARTHRITIS, EXPERIMENTAL; GLUCOSE-6-PHOSPHATE ISOMERASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, TRANSGENIC; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, FC; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 79960509240     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003780     Document Type: Article

References (50)

1. Sanz, I., F. E. Lee; Medscape. 2010. B cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6: 326-337.
2. Tedder, T. F. 2009. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 572-577.
3. Sathasivam, S. 2008. Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Pract. Neurol. 4: 317-327.
4. Schieppati, A., and G. Remuzzi. 2008. Novel therapies of lupus nephritis. Curr. Opin. Nephrol. Hypertens. 17: 156-161.
5. Kazatchkine, M. D., and S. V. Kaveri. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
6. Stangel, M., and R. Pul. 2006. Basic principles of intravenous immunoglobulin (IVIg) treatment. J. Neurol. 253(Suppl. 5): V18-V24.
7. Ballow, M. 1991. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 68: 1430-1436.
8. Kessary-Shoham, H., Y. Levy, Y. Shoenfeld, M. Lorber, and H. Gershon. 1999. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J. Autoimmun. 13: 129-135.
9. Bayry, J., M. D. Kazatchkine, and S. V. Kaveri. 2007. Shortage of human intravenous immunoglobulin: reasons and possible solutions. Nat. Clin. Pract. Neurol. 3: 120-121.
10. Vaccaro, C., J. Zhou, R. J. Ober, and E. S. Ward. 2005. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23: 1283-1288.
11. Petkova, S. B., S. Akilesh, T. J. Sproule, G. J. Christianson, H. Al Khabbaz, A. C. Brown, L. G. Presta, Y. G. Meng, and D. C. Roopenian. 2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 18: 1759-1769.
12. Liu, L., A. M. Garcia, H. Santoro, Y. Zhang, K. McDonnell, J. Dumont, and A. Bitonti. 2007. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J. Immunol. 178: 5390-5398. (Pubitemid 46595326)
13. Huang, H., C. Benoist, and D. Mathis. 2010. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc. Natl. Acad. Sci. USA 107: 4658-4663.
14. Ghetie, V., J. G. Hubbard, J. K. Kim, M. F. Tsen, Y. Lee, and E. S. Ward. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin- deficient mice. Eur. J. Immunol. 26: 690-696.
15. Junghans, R. P., and C. L. Anderson. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93: 5512-5516.
16. Ward, E. S., and R. J. Ober. 2009. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. Adv. Immunol. 103: 77-115.
17. Getman, K. E., and J. P. Balthasar. 2005. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J. Pharm. Sci. 94: 718-729.
18. Mezo, A. R., K. A. McDonnell, C. A. Hehir, S. C. Low, V. J. Palombella, J. M. Stattel, G. D. Kamphaus, C. Fraley, Y. Zhang, J. A. Dumont, and A. J. Bitonti. 2008. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn. Proc. Natl. Acad. Sci. USA 105: 2337-2342.
19. Hansen, R. J., and J. P. Balthasar. 2002. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 100: 2087-2093.
20. Samuelsson, A., T. L. Towers, and J. V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
21. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
22. Bleeker, W. K., J. L. Teeling, and C. E. Hack. 2001. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98: 3136-3142.
23. Li, N., M. Zhao, J. Hilario-Vargas, P. Prisayanh, S. Warren, L. A. Diaz, D. C. Roopenian, and Z. Liu. 2005. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115: 3440-3450.
24. Akilesh, S., S. Petkova, T. J. Sproule, D. J. Shaffer, G. J. Christianson, and D. Roopenian. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113: 1328-1333.
25. Vaccaro, C., R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward. 2006. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc. Natl. Acad. Sci. USA 103: 18709-18714.
26. Ram, S., P. Prabhat, J. Chao, E. S. Ward, and R. J. Ober. 2008. High accuracy 3D quantum dot tracking with multifocal plane microscopy for the study of fast intracellular dynamics in live cells. Biophys. J. 95: 6025-6043.
27. Dall'Acqua, W. F., R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, Y. A. Brewah, H. Wu, P. A. Kiener, and S. Langermann. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169: 5171-5180. (Pubitemid 35217187)
28. Gan, Z., S. Ram, C. Vaccaro, R. J. Ober, and E. S. Ward. 2009. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 10: 600-614.
29. Kouskoff, V., A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87: 811-822. (Pubitemid 26404281)
30. Ji, H., K. Ohmura, U. Mahmood, D. M. Lee, F. M. Hofhuis, S. A. Boackle, K. Takahashi, V. M. Holers, M. Walport, C. Gerard, et al. 2002. Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
31. Korganow, A. S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J. L. Pasquali, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451-461. (Pubitemid 29205481)
32. Maccioni, M., G. Zeder-Lutz, H. Huang, C. Ebel, P. Gerber, J. Hergueux, P. Marchal, V. Duchatelle, C. Degott, M. van Regenmortel, et al. 2002. Arthritogenic monoclonal antibodies from K/B3N mice. J. Exp. Med. 195: 1071-1077.
33. Wipke, B. T., Z. Wang, J. Kim, T. J. McCarthy, and P. M. Allen. 2002. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat. Immunol. 3: 366-372.
34. Roopenian, D. C., G. J. Christianson, T. J. Sproule, A. C. Brown, S. Akilesh, N. Jung, S. Petkova, L. Avanessian, E. Y. Choi, D. J. Shaffer, et al. 2003. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol. 170: 3528-3533. (Pubitemid 36359219)
35. Foote, J., and G. Winter. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224: 487-499.
36. Zhou, J., F. Mateos, R. J. Ober, and E. S. Ward. 2005. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J. Mol. Biol. 345: 1071-1081.
37. Amit, A. G., R. A. Mariuzza, S. E. Phillips, and R. J. Poljak. 1986. Three-dimensional structure of an antigen-antibody complex at 2.8 Å resolution. Science 233: 747-753.
38. Montoyo, H. P., C. Vaccaro, M. Hafner, R. J. Ober, W. Mueller, and E. S. Ward. 2009. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc. Natl. Acad. Sci. USA 106: 2788-2793.
39. Ji, H., D. Gauguier, K. Ohmura, A. Gonzalez, V. Duchatelle, P. Danoy, H. J. Garchon, C. Degott, M. Lathrop, C. Benoist, and D. Mathis. 2001. Genetic influences on the end-stage effector phase of arthritis. J. Exp. Med. 194: 321-330.
40. Anthony, R. M., F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson, and J. V. Ravetch. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376.
41. Chaudhury, C., S. Mehnaz, J. M. Robinson, W. L. Hayton, D. K. Pearl, D. C. Roopenian, and C. L. Anderson. 2003. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197: 315-322.
42. Andersen, J. T., J. Dee Qian, and I. Sandlie. 2006. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur. J. Immunol. 36: 3044-3051.
43. Blumberg, R. S., and W. I. Lencer. 2005. Antibodies in the breakdown lane. Nat. Biotechnol. 23: 1232-1234.
44. Raghavan, M., V. R. Bonagura, S. L. Morrison, and P. J. Bjorkman. 1995. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 34: 14649-14657.
45. Martin, W. L., and P. J. Bjorkman. 1999. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 38: 12639-12647.
46. Schuck, P., C. G. Radu, and E. S. Ward. 1999. Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. Mol. Immunol. 36: 1117-1125.
47. Sánchez, L. M., D. M. Penny, and P. J. Bjorkman. 1999. Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry 38: 9471-9476.
48. Kim, J. K., M. F. Tsen, V. Ghetie, and E. S. Ward. 1994. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand. J. Immunol. 40: 457-465.
49. Tesar, D. B., N. E. Tiangco, and P. J. Bjorkman. 2006. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 7: 1127-1142.
50. Shibuya, N., I. J. Goldstein, W. F. Broekaert, M. Nsimba-Lubaki, B. Peeters, and W. J. Peumans. 1987. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J. Biol. Chem. 262: 1596-1601.